APhA, in a formal comment letter, reiterated its concerns with FDA's list of drugs that present demonstrable difficulties for compounding. APhA's concerns include the agency's decision to identify ...

Independence Blue Cross’s recently announced policy bars coverage of FDA approved treatments until 18 months after accelerated approval. The accelerated approval program was created in 1992 ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the ... [+] risk of heart attacks and strokes. The FDA said Ozempic can be used to reduce the risk of ...

The FDA granted approval to AstraZeneca AZN and partner ... to develop molecular glue degraders for oncology and immunology. Here's a recap of the week’s most important stories.

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

Credit: Genentech. The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water. Each Evrysdi tablet contains 5mg of risdiplam and is ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.